Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 208, Issue 3, Pages 316-322Publisher
OXFORD UNIV PRESS
DOI: 10.1093/cei/uxac045
Keywords
lung cancer; Immunity; Exosomes; PD-L1
Categories
Funding
- National Key R&D Program of China [2016YFC1303300]
- National Natural Science Foundation of China [81672272]
- Shanghai Science and Technology Innovation Program [19411950500]
- Shanghai Municipal Science and Technology Commission Research Project [17431906103]
- Shanghai Chest Hospital Project of Collaborative Innovation [YJXT20190105]
Ask authors/readers for more resources
This study found that exosomal PD-L1 is associated with the clinical response to immunotherapy in NSCLC patients and can be used as a biomarker to predict the efficacy of ICIs. NSCLC patients with lower expression level of exosomal PD-L1 at pre-treatment or higher max fold increasing change at 3-6 weeks had higher disease control rate and longer progression-free survival.
Immune Check-Point Inhibitors (ICIs) have shown remarkable promise in treating tumors, including non-small cell lung cancer (NSCLC). Nevertheless, the treatment response rate is low. Studies have found that the high expression of exosomal PD-L1 is one of the reasons for the low treatment response. Therefore, this study focused on the relationship between the exosomal PD-L1 and the clinical response to immunotherapy in NSCLC patients to evaluate whether it could be used as a biomarker to predict the efficacy of ICIs. In this study, clinical information and blood samples of 149 NSCLC patients receiving ICIs were collected. The expression level of exosomal PD-L1 was detected by enzyme-linked immunosorbent assay method, and the relationship between exosomal PD-L1 and the efficacy of ICIs was explored. Overall, our study found that the expression level of exosomal PD-L1 was lower at pre-treatment, or the max fold increasing change higher at 3-6 weeks had a higher disease control rate and longer progression-free survival. It revealed that the exosomal PD-L1 was associated with the treatment response of patients using ICIs and provided a new tool for the evaluation of clinical efficacy of lung cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available